tance of PR expression in the pathogenesis of intrauterine growth restriction, as there were direct correlations of PR expression with both IGF-I expression and infant anthropometric parameters, as well as gestational age.
Introduction
Fetal growth restriction is a complex problem of pregnancy, arising from multiple etiologies, including environmental, nutritional and genetic problems [1] . The genetic factors tend to contribute towards early growth restriction, particularly in the first and second trimesters, whereas nutritional and environmental factors predominantly influence growth in the latter part of pregnancy, contributing to the phenomenon of maternal constraint, whereby normal fetal growth is affected by maternal size. A significant component of metabolic regulation is that of hormone-endocrine pathways, the most significant of these being the paracrine insulin-like growth factor (IGF) system. Deficiencies in this system contribute to fetal growth problems, with the outcome being that of babies born with a low birth weight (LBW), or, more specifically, small for their gestational age (SGA). Additionally, increases in metabolic factors may also adversely contrib-ute to excessive fetal growth [2] . These growth disorders may have profound effects on postnatal growth and development, increasing the risks of both immediate perinatal morbidity and mortality. SGA therefore constitutes a significant clinical and public health problem, globally, affecting more than 30 million newborns per year [3, 4] . Furthermore, a well-established cause of intrauterine growth restriction (IUGR) is that of the clinical syndrome preeclampsia , which is defined as a combination of an increased diastolic blood pressure ( 1 90 mm Hg), along with proteinurea [5] . The degrees of proteinurea further grade the syndrome into mild and severe [6, 7] .
The IGF system consists of the growth factors, IGF-I and IGF-II, the binding proteins (IGFBPs 1-6), proteases, and their signaling receptor (IGF-I-R). In pregnancy, the key binding protein is that of IGFBP-1, which binds to and delivers the growth factors, IGF-I and -II, directly to fetal tissue cell surfaces, activating cellular mitotic processes, promoting cellular and tissue growth. The IGFs are therefore paramount to normal cellular growth, with the relationship between IGF-I and -II, and IGFBP-1 in the placenta of children born SGA being a well-established one [8] . In addition to the IGF system, key maternal steroid hormone receptors are believed to influence placental function and growth, namely, the estrogen and progesterone receptors. Estrogen is believed to indirectly promote growth, both in utero and in postnatal life, through the activation of estromedins , a group of estrogen-induced growth factors, which principally act through the actions of the estrogen receptor in the maternal endometrium [9] . The estrogen receptor comprises of two main isoforms, ␣ and ␤ (ER ␣ and ER ␤ , respectively), which show significant overall sequence homology and function, and therefore share similar affinities in estradiol binding. Additionally, the estromedins are thought to activate paracrine growth factors, namely IGF-I, which further mediate stromal-epithelial cell interactions to facilitate the growth response, particularly in the later stages of pregnancy [9] .
Increases in progesterone hormone levels are also seen in pregnancy, with a subsequent up-regulation of its receptor in the endometrium. This PR comprises of two major isoforms (PRA and PRB), both of which are dependent on estrogen for transcription and expression [10] . More specifically, PRA has been shown to down-regulate transcription of the growth-promoting PRB. In contrast, PRB levels inhibit IGFBP-1 synthesis, with a resultant increase in free IGF-I and -II, thereby asserting a growthpromoting effect [11] . PRB is more abundantly seen in the uterus throughout pregnancy, whereas PRA levels have been seen to increase after the onset of labor [12] . We therefore hypothesize that lower levels of ER ␣ , ER ␤ , and PRB are contributing factors towards the development of FGR and SGA pregnancies. The principal aims of this study were, therefore, to quantify mRNA expression levels of ER ␣ , ER ␤ , PR and IGF-I in the placentas of growthrestricted and normal-birth-weight babies in the Swedish population. Additionally, to correlate these expression levels with maternal and infant anthropometric variables for potential uses as markers of growth restriction.
Materials and Methods

Population Characteristics
Placental samples were obtained following informed consent from 33 patients, following delivery during 1997-1998, at the Karolinska University Hospital, Stockholm, Sweden. The samples were divided into two major groups: normal control (NC, n = 14), and growth-restricted (GR, n = 19). For descriptive purposes, the GR group was further divided on the basis of the presence of preeclampsia as follows: intrauterine growth-restricted (IUGR, n = 9), mild preeclampsia with IUGR (MPE, n = 5), and severe preeclampsia with IUGR (SPE, n = 5). The GR samples included babies with IUGR with or without preeclampsia. Tissue specimens were immediately frozen in liquid nitrogen and stored at -70 ° C for subsequent transport and analysis. Furthermore, maternal height, weight, and gestational age were recorded at the time of admission, prior to delivery. Additionally, mode of delivery was also documented. Archived birth records were consulted for information regarding all anthropometric variables.
Solution Hybridization Analyses of mRNAs
Total Nucleic Acid Purification Total nucleic acids (TNA) were prepared as described by Sahlin [13] . Briefly, after thawing the tissues were homogenized and digested with proteinase K (Merck, Darmstadt, Germany) in an SDS-containing buffer, followed by subsequent extraction with phenol-chloroform as described by Durnam and Palmiter [14] . The DNA content of the TNA samples was determined by a fluorometric assay at the wavelength 458 nm with Hoechst Dye 33258 [15] .
Hybridization Probes ER ␣ . The probe used for the ER ␣ mRNA determinations was derived from bcpe1 , a full-length cDNA containing the whole open reading frame of the human estrogen receptor. The cDNA was inserted in a pGEM7zf vector. Restriction of this vector with Bgl II allows the synthesis of a 576-bp antisense probe, complementary to the sequence encoding the C-terminal half of the steroid-binding domain (E) and all of domain F [16] .
ER ␤ . The probe used for ER ␤ mRNA determinations was derived from a pBS plasmid with an insert of a 187-bp Pvu II/ Eco RI fragment corresponding to nucleotides 774-979 in the human ER ␤ gene [17] .
PR. The probe utilized to assess the PR mRNA expression was derived from a full-length cDNA containing the entire open read-133 ing frame of the human PR. The cDNA was subsequently inserted into a pGEM3Z vector, which was further restricted with Bc l I. The synthesized probe corresponded to nucleotides 2065-2838, which encode the C-terminal part of the ligand-binding domain (E) [18] . Thus, the probe recognizes the PR isoforms that are truncated at the N-terminal.
IGF-I . IGF-I mRNA expression was determined using a probe derived from a 775-bp Rsa I-Eco RI cDNA fragment of human IGF-I. This fragment was cloned into the Hin cII and Eco RI sites of a Bluescript KS vector, with subsequent restriction with Xho I to synthesize the probe [19] .
Hybridization Analysis of mRNA For measurements of specific mRNA, probes were synthesized in vitro and radiolabeled with 35 S-UTP (Amersham, Bucks., UK). The in vitro synthesis of radioactive cRNA was performed as described by Melton et al. [20] , using reagents supplied from Promega Biotech (Madison, Wisc., USA).
35 S-UTP-labeled cRNA was hybridized (20,000-40,000 cpm per incubation) at 70 ° C to TNA samples as described by Mathews et al. [21] . Incubations were performed in duplicate in microcentrifuge tubes (Treff AG, Degersheim, Switzerland) in a total volume of 40 l containing 0.6 mol l -1 NaCl, 22 mmol l -1 Tris-HCl pH 7.5, 5 mmol l -1 EDTA, 0.1% SDS, 0.75 mmol l -1 dithiothreitol, and 25% formamide. After overnight incubation under paraffin oil, each sample was treated for 45 min at 37 ° C with 1 ml RNase buffer containing 0.3 mol l -1 NaCl, 10 mmol l -1 Tris pH 7.5, 2 mmol l -1 EDTA, 40 g RNase A, 118 units RNase T1 (Boehringer-Mannheim, Mannheim, Germany) and 100 g calf thymus DNA, to digest non-hybridized RNA. Labeled hybrids protected from RNase digestion were precipitated by addition of 100 l of 6 mol l -1 trichloroacetic acid and collected on filters (Whatman GF/C). The radioactivity on the filters was determined in a liquid scintillation counter and the results were compared with a standard curve of known amounts of in vitro synthesized mRNA complementary to the probe used. Results are expressed as amol (10 -18 ) mRNA/ g DNA in the TNA samples.
Statistical Analysis
Statistical analysis was performed using the Student's t test, Pearson's correlation test, and one-way ANOVA. ANOVA was conducted using the NC group as the dependent factor. Post-hoc significance for ANOVA was evaluated using the Waller-Duncan correction. Values are given as mean 8 SEM. A p value of ! 0.05 was considered as statistically significant.
Ethical Considerations
Ethical approval was obtained from the Northern Stockholm Ethical Committee, Stockholm, Sweden. Written consent was obtained from all patients.
Results
Population Characteristics
The study population was divided into four groups, as mentioned above. Comparisons of maternal weight (kg), height (m), and BMI between these groups showed no statistical significance, though maternal BMI was marginally lower in the SPE group. The placental mRNA expression for the receptors, ER ␣ , ER ␤ , and PR, and the peptide hormone, IGF-I, are shown in figure 1 . Significant differences in IGF-I expression were seen between all groups when compared to the NC (p ! 0.05, ANOVA). No statistically significant differences were seen with ER ␣ , ER ␤ , or PR, comparing between the groups. Of interest to note is the decreased expression of ER ␣ , ER ␤ , PR and IGF-I in the SPE group ( fig. 1 ). Significant differences in modes of delivery were also noted, with the majority of babies being born with acute cesarean sections in the GR groups, as compared to elective cesarean sections and spontaneous vaginal deliveries in the NC group (p ! 0.001).
Descriptive statistics of maternal and infant anthropometric characteristics, receptor expression levels, and measured hormone levels along with their levels of significance are shown in table 1 (NC and GR groups). As can be seen in the table, birth weight, birth height and IGF-I levels were significantly lower in the GR group as compared to the NC group (p ! 0.01). Additionally, comparisons of mean gestational ages at the time of delivery (in weeks) between the two groups showed a tendency towards a lower mean gestational age in the GR group (p = 0.06). No significant differences were seen in the expression levels of the receptors, ER ␣ , ER ␤ , and PR, comparing the GR group NC group.
Anthropometric Correlations with the ER ␣ , ER ␤ , PR, and IGF-I
Further analysis using Pearson's correlation showed significant relationships between several of the anthropometric factors within both groups. These can be seen more clearly in table 2 . Table 2 a, representing the NC, shows significant correlations between placental ER ␤ expression and maternal weight at delivery (r = -0.87, p ! 0.05) and gestational age (in weeks, r = 0.50, p ! 0.05); placental ER ␣ and PR mRNA levels (r = 0.70, p ! 0.05); IGF-I expression and infant birth height (r = 0.99, p ! 0.01). Of interest to note is that the correlation between maternal weight and placental ER ␤ mRNA is negative, whereas that of placental IGF-I mRNA and birth height is positive. Furthermore, a positive correlation trend is noted between IGF-I and ER ␣ (r = 0.52, p = 0.07). Though not significant, a positive correlation was seen between IGF-I expression and the gestational age in weeks (r = 0.44, p = 0.07). Ta 
Discussion
The aims of the study were to ascertain the placental expression levels of IGF-I, ER ␣ , ER ␤ , and PR, comparing NC and GR groups in the Swedish population. Furthermore, we correlated these expression levels with anthropometric variables. This is the first study of its kind looking into the associations of placental expression of the F or the purposes of statistical analysis, all the intrauterine growth-restricted infants were combined into one group (GR). All means are given with their SEM. All values are given in SI units. Significant differences were seen in infant birth weight, birth height, and IGF-I mRNA levels when comparing the two groups. The level of significance was defined as p < 0.05, evaluated by Student's t test.
steroid receptors, ER ␣ , ER ␤ , and PR, with maternal and infant anthropometry. We have shown significant differences in expression levels of IGF-I, along with significant correlations of receptor expression and both maternal and infant anthropometry, and gestational age at the time of delivery. Previous studies have emphasized the significance of the steroid hormones and their receptors on the regulation of growth factors in endometrial tissue, though none have looked at correlations with birth weight outcomes and anthropometry [9, 22] . Furthermore, we have previously shown similar significant differences in IGF-I levels in a different ethnic group, whereby IGF-I significantly correlated to maternal and infant anthropometry in the Pakistani population [23] . Our previous results also emphasize the differences in levels of placental IGF-I with respect to birth weight and height outcomes.
The growth factor, IGF-I, plays a key role in fetal and placental growth and development throughout pregnancy [24] . Our results showed significantly higher levels of IGF-I in the NC group as compared to the GR groups. These results are in keeping with previous findings, where lower IGF-I and IGF-II placental mRNA levels have been associated with babies being born SGA [23] . Ozkan et al. [25] have also shown decreased IGF-I expression in preeclampsia, where IGF-I inhibition is believed to be one of the key mechanisms behind the development of this clinical problem, though the exact mechanism is still unclear. The differences in expression levels of IGF-I, with lower levels seen in the GR group, could be due to increased fetal hypoxic strain leading to a subsequent down-regulation of the growth factor pathway, modulating cellular and tissue growth in an already 'strained' fetal environment [26] . Allan et al. [27] have emphasized the importance of this fine balance and the physiological and genetic role of IGF-I in cellular and tissue growth and development.
The estrogen receptors play an important role in cellular and tissue growth as well as in pathological conditions, namely preeclampsia and HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) [28, 29] . These findings outline the regulatory role of the receptor on both cellular development and 'normal' functioning. We found significant correlations of ER ␣ and ER ␤ expression and maternal weight and BMI in the subgroups at the time of delivery, though, interestingly, the correlation of ER ␤ with maternal weight at the time of delivery, in the NC group, was a negative one. This suggests that increased maternal weight negatively regulates the expression of ER ␤ in the human placenta. The pivotal role of these receptors in the pathogenesis of pregnancy-related diseases and outcomes is evident, and we therefore suggest that further trials be conducted to study the mechanisms underlying this relationship.
A second key steroid receptor in the regulatory pathway of normal growth and development in pregnancy is that of the PR. Gao and Tseng [11] have shown the importance of this receptor in regulating IGFBP-1 in human endometrial cells. The PR belongs to a superfamily of ligand-induced transactivators, thereby allowing progesterone to bind to specific DNA sequences, activating gene transcription [30] . This, in turn, regulates the transcription and expression of other growth-promoting factors. Our results showed no significant difference in levels of PR expression between the groups, GR and NC. This may be due to the fact that increases in PR are principally associated with the onset of labor and may thus explain the lack of difference in levels in both patient groups [12, 31] . Interestingly, placental PR mRNA expression levels were significantly correlated to IGF-I mRNA expression, gestational age, and to infant birth height and weight, in the GR group, suggesting that this nuclear receptor may indeed play a role in placental IGF-I regulation and fetoplacental growth. Lower placental expression levels of IGF-I were seen in the GR as compared to NC group in the absence of any significant differences in PR expression between the groups. This further suggests the complex multifactorial relationship of IGF-I expression, independent of steroid hormone expression, in the pathogenesis of growth restriction.
In summary, we have, for the first time, shown significant differences in placental IGF-I expression levels, and significant correlations of the placental expression of the steroid receptors, ER ␣ , ER ␤ , and PR, with both IGF-I and maternal and infant anthropometry in GR infants. We have also shown significant correlations of hormone receptor expression and IGF-I with gestational age, in both groups. Our data supports previous results of the role of IGF-I in fetoplacental growth [24] . Additionally, we looked at these variables within a population subgroup with the clinical syndrome, preeclampsia. The changes in levels of these receptors and hormones in GR and preeclampsia suggest their role in the pathogenesis of these clinical problems. We have shown that the differences in placental growth factor expression are present irrespective of ethnicity and therefore suggest a common underlying mechanism of growth restriction, irrespective of differences in population genetics. Our results suggest the possible roles of ER and PR expression in the pathogenesis of both fetal growth restriction and preeclampsia, with lower levels contributing to higher likelihoods of disease outcome. Modalities to increase the expression of these receptors, with a subsequent increase in hormone receptor binding and activation of cellular growth pathways, could therefore be used as possible interventions in the prevention of fetal growth restriction.
